How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,691 results for

Preeclampsia Prevention

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history

Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history The Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention trial demonstrated that in women who were at high risk for preterm preeclampsia with delivery at <37 weeks' gestation identified by screening by means of an algorithm (...) that combines maternal factors and biomarkers at 11-13 weeks' gestation, aspirin administration from 11 to 14 until 36 weeks' gestation was associated with a significant reduction in the incidence of preterm preeclampsia (odds ratio 0.38; 95% confidence interval, 0.20 to 0.74; P=0.004).We sought to examine whether there are differences in the effect of aspirin on the incidence of preterm preeclampsia in the Aspirin for Evidence-Based Preeclampsia Prevention trial in subgroups defined according to maternal

Full Text available with Trip Pro

2018 EvidenceUpdates

2. Cluster analysis to estimate the risk of preeclampsia in the high-risk Prediction and Prevention of Preeclampsia and Intrauterine Growth Restriction (PREDO) study. (PubMed)

Cluster analysis to estimate the risk of preeclampsia in the high-risk Prediction and Prevention of Preeclampsia and Intrauterine Growth Restriction (PREDO) study. Preeclampsia is divided into early-onset (delivery before 34 weeks of gestation) and late-onset (delivery at or after 34 weeks) subtypes, which may rise from different etiopathogenic backgrounds. Early-onset disease is associated with placental dysfunction. Late-onset disease develops predominantly due to metabolic disturbances (...) , obesity, diabetes, lipid dysfunction, and inflammation, which affect endothelial function. Our aim was to use cluster analysis to investigate clinical factors predicting the onset and severity of preeclampsia in a cohort of women with known clinical risk factors.We recruited 903 pregnant women with risk factors for preeclampsia at gestational weeks 12+0-13+6. Each individual outcome diagnosis was independently verified from medical records. We applied a Bayesian clustering algorithm to classify

Full Text available with Trip Pro

2017 PLoS ONE

3. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit

Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit Preeclampsia is a major pregnancy complication with adverse short- and long-term implications for both the mother and baby. Screening for preeclampsia at 11-13 weeks' gestation by a combination of maternal demographic characteristics and medical history with measurements of biomarkers can identify about 75% of women who develop preterm preeclampsia with delivery (...) at <37 weeks' gestation and 90% of those with early preeclampsia at <32 weeks, at a screen-positive rate of 10%. A recent trial (Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention) has reported that in women identified by first-trimester screening as being at high risk for preeclampsia, use of aspirin (150 mg/d from the first to the third trimester), compared to placebo, reduced the incidence of preterm preeclampsia, which

Full Text available with Trip Pro

2018 EvidenceUpdates

4. Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage

Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage Impaired placentation in the first 16 weeks of pregnancy is associated with increased risk of subsequent development of preeclampsia, birth of small-for-gestational-age neonates, and placental abruption. Previous studies reported that prophylactic use of aspirin reduces the risk of preeclampsia and small-for-gestational-age neonates with no significant effect on placental (...) was significant (P=.04).Aspirin at a daily dose of ≥100 mg for prevention of preeclampsia that is initiated at ≤16 weeks of gestation, rather than >16 weeks, may decrease the risk of placental abruption or antepartum hemorrhage.Copyright © 2018 Elsevier Inc. All rights reserved.

Full Text available with Trip Pro

2018 EvidenceUpdates

5. Torsemide for Prevention of Persistent Postpartum Hypertension in Women With Preeclampsia: A Randomized Controlled Trial

Torsemide for Prevention of Persistent Postpartum Hypertension in Women With Preeclampsia: A Randomized Controlled Trial To evaluate whether torsemide reduces the rate of persistent postpartum hypertension in women with preeclampsia.We conducted a randomized, double-blind, placebo-controlled trial of women with preeclampsia at a tertiary center from August 2016 to September 2017. Those with gestational hypertension or renal or cardiopulmonary failure were excluded. Within 24 hours of delivery (...) , women were randomized one to one to oral torsemide, 20 mg/d, or placebo, for 5 days. Our primary outcome was blood pressure greater than or equal to 150 mm Hg systolic or 100 mm Hg diastolic (or both) on two occasions at least 4 hours apart by postpartum day 5 or by the time of hospital discharge. Assuming a 50% rate of persistent hypertension in women with preeclampsia, 118 participants were required to detect a 50% rate reduction. Analyses were by intention to treat.From August 2016 to September

2018 EvidenceUpdates

6. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication

Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication Final Update Summary: Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive (...) Medication Release Date: September 2014 Recommendation Summary Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia Population Recommendation Grade Pregnant Women Who Are At High Risk for Preeclampsia The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. ( ) Related Information for Consumers Related Information for Health Professionals There is no related information

2014 U.S. Preventive Services Task Force

7. The Effects of Vitamin D Supplement on Prevention of Recurrence of Preeclampsia in Pregnant Women with a History of Preeclampsia (PubMed)

The Effects of Vitamin D Supplement on Prevention of Recurrence of Preeclampsia in Pregnant Women with a History of Preeclampsia Preeclampsia is a pregnancy-specific syndrome. One of the hypotheses concerning the etiology of preeclampsia is vitamin D deficiency during pregnancy.The present study is a randomized controlled clinical trial which aims to determine the effect of vitamin D supplement on reducing the probability of recurrent preeclampsia. 72 patients were placed in control group while (...) 70 patients were randomized to the intervention group. The intervention group received a 50000 IU pearl vitamin D3 once every two weeks. The control group was administered placebo. Vitamin D or placebo was given until the 36th week of pregnancy.The patients in intervention group have significantly lower (P value = 0.036) probability of preeclampsia than patients in the control group. The risk of preeclampsia for the control group was 1.94 times higher than that for the intervention group (95% CI

Full Text available with Trip Pro

2017 Obstetrics and gynecology international

8. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. (PubMed)

Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. Preeclampsia affects approximately 4% of pregnancies in the United States. It is the second leading cause of maternal mortality worldwide and may lead to serious maternal complications, including stroke, eclampsia, and organ failure. Adverse perinatal outcomes for the fetus and newborn include intrauterine growth restriction, low birth weight, and stillbirth. Many of the complications associated (...) to poor outcomes associated with preeclampsia in African American women.To update the 1996 US Preventive Services Task Force (USPSTF) recommendation on screening for preeclampsia.The USPSTF reviewed the evidence on the accuracy of screening and diagnostic tests for preeclampsia, the potential benefits and harms of screening for preeclampsia, the effectiveness of risk prediction tools, and the benefits and harms of treatment of screen-detected preeclampsia.Given the evidence that treatment can reduce

Full Text available with Trip Pro

2017 JAMA

9. Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. Preeclampsia is a complex disease of pregnancy with sometimes serious effects on maternal and infant morbidity and mortality. It is defined by hypertension after 20 weeks' gestation and proteinuria or other evidence of multisystem involvement.To systematically review the benefits and harms of preeclampsia screening and risk assessment for the US Preventive Services Task Force.MEDLINE, PubMed (...) , and Cochrane Central Register of Controlled Trials databases from 1990 through September 1, 2015. Surveillance for new evidence in targeted publications was conducted through October 5, 2016.English-language trials and observational studies, including externally validated prediction models, of screening effectiveness, benefits, and harms from routine preeclampsia screening during pregnancy.Independent dual review of article abstracts and full texts against a priori inclusion criteria. Meta-analysis

Full Text available with Trip Pro

2017 JAMA

10. Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia

Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) period of aspirin use for prevention of preeclampsia Article Text Therapeutics/Prevention Systematic review Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Free Paul Leeson Statistics from Altmetric.com Commentary on : Henderson JT , Whitlock EP , O'Connor E , et al . Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the US Preventive Services Task

Full Text available with Trip Pro

2015 Evidence-Based Medicine (Requires free registration)

11. Preeclampsia

of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Top results for preeclampsia 1. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history 28784417 2017 11 16 2018 01 11 1097-6868 217 5 2017 11 American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Aspirin for Evidence-Based Preeclampsia Prevention (...) trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according (...) to their characteristics and medical and obstetrical history. 585.e1-585.e5 S0002-9378(17)30929-8 10.1016/j.ajog.2017.07.038 The Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention trial demonstrated that in women who were at high risk for preterm preeclampsia with delivery at 2018 2. Preeclampsia : Screening Final Recommendation

2018 Trip Latest and Greatest

12. A Randomized Double-Blinded Placebo-Controlled Intervention Trial of Melatonin for the Prevention of Preeclampsia in Moderate- and High-Risk Women: The MELPOP Trial. (PubMed)

A Randomized Double-Blinded Placebo-Controlled Intervention Trial of Melatonin for the Prevention of Preeclampsia in Moderate- and High-Risk Women: The MELPOP Trial. This chapter describes the methodologies which may be used in the development of a randomized controlled trial investigating a therapy of choice in preventing preeclampsia.

2018 Methods in molecular biology (Clifton, N.J.)

13. Prophylactic magnesium sulphate in prevention of eclampsia in women with severe preeclampsia: randomised controlled trial (PIPES trial). (PubMed)

Prophylactic magnesium sulphate in prevention of eclampsia in women with severe preeclampsia: randomised controlled trial (PIPES trial). Optimum dose, route and duration of use of prophylactic magnesium sulphate in women with severe pre-eclampsia is still controversial. We compared the efficacy and safety of 'low-dose Dhaka' regime with 'Loading dose only' regime for seizure prophylaxis in severe preeclampsia using a randomised controlled trial in 402 women. The incidence of eclampsia (...) preeclampsia. Impact statement What is already known on this subject: Efficacy of therapeutic short regime magnesium sulphate in eclampsia has already been reported. Data regarding prophylactic short regime in women with preeclampsia is sparse. What the results of this study add: We have shown that short regime of magnesium sulphate using only the loading dose in the prevention of seizure in preeclampsia is an effective alternative to the low-dose Dhaka regime. What the implications are of these findings

2018 Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology

14. Nutritional approach to preeclampsia prevention. (PubMed)

Nutritional approach to preeclampsia prevention. Although not fully understood, the physiopathology of preeclampsia is thought to involve an abnormal placentation, diffuse endothelial cell dysfunction and increased systemic inflammation. As micronutrients play a key role in placental endothelial function, oxidative stress and expression of angiogenic factors, periconceptional micronutrient supplementation has been proposed to reduce the risk of preeclampsia. However, recent studies reported (...) conflicting results.Calcium intake (>1 g/day) may reduce the risk of preeclampsia in women with low-calcium diet. Data from recently updated Cochrane reviews did not support routine supplementation of vitamins C, E or D for either the prevention or treatment of preeclampsia. Evidences are also poor to support zinc or folic acid supplementation for preeclampsia prevention. Dark chocolate, flavonoid-rich food, and long-chain polyunsaturated fatty acids might also be candidates for prevention

2018 Current opinion in clinical nutrition and metabolic care

15. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. (PubMed)

Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. We have performed a systematic search to summarize the role of statins for preventing and treating severe preeclampsia.The aim of this study was to examine whether pravastatin is a useful and safe alternative for treating preeclampsia during pregnancy.A systematic MEDLINE (PubMed) search was performed (1979 to June 2017), which was restricted to articles published in English, using the relevant key words of "statins (...) in the antiphospholipid syndrome (25 studies), statin's specific use during pregnancy (13 studies), or preeclampsia treatment (11 studies).Although the studies are of poor quality, the rate of major congenital abnormalities in the newborn exposed to statins during pregnancy is no higher than the expected when compared with overall risk population. The review shows a potential beneficial role of statins in preventing and treating severe preeclampsia that needs to be evaluated through well-designed clinical trials.This

2018 Obstetrical & Gynecological Survey

16. Aspirin for Prevention of Preeclampsia in Healthy, Nulliparous Obese and Overweight Pregnant Women

Aspirin for Prevention of Preeclampsia in Healthy, Nulliparous Obese and Overweight Pregnant Women Aspirin for Prevention of Preeclampsia in Healthy, Nulliparous Obese and Overweight Pregnant Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Aspirin for Prevention of Preeclampsia in Healthy, Nulliparous Obese and Overweight Pregnant Women The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03725891 Recruitment Status

2018 Clinical Trials

17. ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies

ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. ASA Patterns for Prevention (...) Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Randomized Control Trial Masking: None (Open Label) Primary Purpose: Other Official Title: Aspirin Patterns of Use and Adherence for Prevention of Preeclampsia in SLE Pregnancies Actual Study Start Date : May 28, 2018 Estimated Primary Completion Date : October 31, 2019 Estimated Study Completion Date : November 30, 2022 Resource links provided by the National Library of Medicine related topics: available

2018 Clinical Trials

18. Molecular actions of heparin and their implications in preventing preeclampsia. (PubMed)

Molecular actions of heparin and their implications in preventing preeclampsia. Pre-eclampsia, a hypertensive disorder of pregnancy, continues to be a significant cause of global maternal morbidity. Low-dose aspirin remains the only standard-of-care prophylactic therapy for preventing pre-eclampsia, but is limited in efficacy. Heparin and its derivatives may further enhance the efficacy of aspirin therapy to prevent pre-eclampsia, but the mechanisms mediating this augmentative effect (...) are not known. Although heparin is an anticoagulant agent, it also possesses many anticoagulant-independent properties that may be relevant in the prevention of pre-eclampsia, including effects on placental, vascular and inflammatory function. This review summarizes the non-anticoagulant properties of heparin, and extrapolates how these actions may influence the trajectory of pre-eclampsia pathogenesis as a means of pathway-specific therapy.© 2018 International Society on Thrombosis and Haemostasis.

2018 Journal of Thrombosis and Haemostasis

19. Maternal folic acid supplementation for the prevention of preeclampsia: A systematic review and meta-analysis. (PubMed)

Maternal folic acid supplementation for the prevention of preeclampsia: A systematic review and meta-analysis. Preeclampsia is a significant contributor to maternal and neonatal morbidity and mortality. Folic acid supplementation is recommended periconceptionally for the prevention of neural tube defects. Epidemiological evidence suggests that maternal folic acid supplementation may play a role in preventing other adverse birth outcomes. This systematic review aimed to investigate the effect (...) of maternal folic acid supplementation during pregnancy on risk of preeclampsia and gestational hypertension.Multiple scientific databases and grey literature were searched for relevant studies. Studies were reviewed according to pre-specified inclusion and exclusion criteria. Study characteristics were summarised and study quality was assessed. A meta-analysis of observational studies was conducted to examine the effect of maternal folic acid supplementation on preeclampsia risk.Meta-analysis of eight

2018 Paediatric and perinatal epidemiology

20. Feasibility of integrating calcium and iron-folate supplementation to prevent preeclampsia and anemia in pregnancy in primary healthcare facilities in Kenya. (PubMed)

Feasibility of integrating calcium and iron-folate supplementation to prevent preeclampsia and anemia in pregnancy in primary healthcare facilities in Kenya. Calcium (Ca) supplementation to prevent preeclampsia can save maternal and newborn lives, but there are no program models for integration into existing antenatal care platforms. We used a program impact pathway model to guide the design of integrated Ca and iron-folate (IFA) supplementation in Kenya. We provided healthcare providers

Full Text available with Trip Pro

2018 Maternal & child nutrition

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>